Dr. Reddy’s Laboratories has unveiled Nerivio, an innovative, FDA-approved wearable therapy device designed for the drug-free management of migraines, marking the company’s foray into the realm of digital therapeutics (DTx). M.V. Ramana, the CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, emphasized the growing acceptance of DTx among physicians and patients. Nerivio, a non-invasive solution with a favorable safety profile, is a groundbreaking product for migraine sufferers in India.
Ramana acknowledged the continued success of their core generics business and highlighted Nerivio’s integration into their e-commerce venture, Celevida Wellness. Migraine, a pervasive global health issue affecting up to 30% of adults, has a particularly significant impact on women, constituting 60% of the 213 million sufferers in India alone.
Nerivio, a prescription-based device worn on the upper arm, offers acute and preventive migraine treatment for adults and adolescents. Priced at ₹14,000, along with a patient support program, it equates to ₹777 per treatment session. Utilizing Remote Electrical Neuromodulation (REN), Nerivio activates conditioned pain modulation, providing natural pain relief.
Accompanied by the user-friendly Nerivio app, available on both the Google Play Store and the Apple App Store, the device allows users to control intensity levels. Dr. Reddy’s comprehensive patient support program, M-Free, enhances the patient journey, making Nerivio a promising advancement in migraine care.
